Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE program, 2009-2011

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 4, 2014, Pages 437-442

  Flamm, Robert K ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

AWARE; Ceftaroline; S. pneumoniae; USA

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAROLINE; CEFTRIAXONE; PENICILLIN DERIVATIVE;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VERY ELDERLY;

AWARE; CEFTAROLINE; S. PNEUMONIAE; USA;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; UNITED STATES; YOUNG ADULT;

EID: 84895895649     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.10.020     Document Type: Article

References (25)

1. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010, 65(Suppl 4):iv9-iv16.
2. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9 2012, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
4. Critchley I.A., Eckburg P.B., Jandourek A., Biek D., Friedland H.D., Thye D.A. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011, 66(Suppl 3):iii45-iii51.
5. Farrell D.J., Castanheira M., Mendes R.E., Sader H.S., Jones R.N. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis 2012, 55(Suppl 3):S206-S214.
6. File T.M. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006, 12(Suppl 3):31-41.
7. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
8. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012, 56:2933-2940.
9. Jacobs M.R., Good C.E., Windau A.R., Bajaksouzian S., Biek D., Critchley I.A., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010, 54:2716-2719.
10. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010, 68:334-336.
11. Jones R.N., Farrell D.J., Mendes R.E., Sader H.S. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl 3):iii69-iii80.
12. Karlowsky J.A., Adam H.J., Decorby M.R., Lagace-Wiens P.R., Hoban D.J., Zhanel G.G. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009. Antimicrob Agents Chemother 2011, 55:2837-2846.
13. Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., Johannes R.S. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
14. Laudano J.B. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011, 66(Suppl 3):iii11-iii18.
15. McGee L., Biek D., Ge Y., Klugman M., du Plessis M., Smith A.M., et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009, 53:552-556.
16. Morrissey I., Leakey A. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08). J Antimicrob Chemother 2012, 67:1408-1412.
17. Pfaller M.A., Farrell D.J., Sader H.S., Jones R.N. AWARE ceftaroline surveillance program (2008-2010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(Suppl 3):S187-S193.
18. Rank D.R., Friedland H.D., Laudano J.B. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011, 66:iii53-iii59.
19. Sader H.S., Flamm R.K., Farrell D.J., Jones R.N. Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. Clin Infect Dis 2012, 55(Suppl 3):S181-S186.
20. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010, 54:3027-3030.
21. Teflaro® Package Insert New York City, NY Available at, Accessed August 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200327s009lbl.pdf.
22. Tygacil Package Insert Wyeth Pharmaceuticals, Philadelphia, PA Available at, Accessed January 2013. http://www.tygacil.com.
23. Versalovic J., Carroll K.C., Funke G., Jorgensen J., Landry M.L., Warnock D.W. Manual of clinical microbiology 2011, ASM Press, Washington D.C. 10th ed.
24. VIBATIV Package Insert Package Insert Available at, Accessed November 2013. http://www.vibativ.com.
25. Vidaillac C., Leonard S.N., Rybak M.J. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents 2010, 35:527-530.